Genmab enters agreement on cancer biomarker

A supply agreement will give the Danish firm access to US-based biotech company Imaginab’s oncology imaging technology in future clinical trials.

Photo: Tuala Hjarnø / Genmab / PR

Danish biotech firm Genmab has struck a supply deal with Imaginab, a US-based biotech firm that is developing imaging technology for cancer treatments, the latter firm has announced in a press release.

Through the agreement, Genmab gains access to use the biomarker CD8 ImmunoPET, an antibody fragment that binds to the body’s CD8 T cells, in clinical trials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs